These findings suggest that dysregulated resolution of semaphorin signaling, particularly involving SEMA4D and SEMA7A, may be associated with adverse outcomes and impaired immunological recovery in sCAP. Here, SEMA4D is linked to syringocystadenoma papilliferum.